048530 — iNtRON Biotechnology Share Price
0.000.00%
Last trade - 00:00- KR₩130bn
- KR₩82bn
- KR₩6bn
- 39
- 20
- 26
- 14
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.59 | ||
| Price to Tang. Book | 1.62 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 20.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.16% | ||
| Return on Equity | -2.87% | ||
| Operating Margin | -81.61% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 45,433.16 | 29,308.01 | 14,006.98 | 9,585.44 | 6,417.83 | n/a | n/a | -5.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -20.21 | -99.69 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
iNtRON Biotechnology, Inc. is a Korea-based company principally engaged in the biotechnology industry. The Company operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. It also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The Company distributes its products within domestic market and to overseas markets.
Directors
- Seong Jun Yoon CEO (44)
- Gyeong Won Yoon MDR (41)
- Sang Hyeon Kang MDR (45)
- Jae Gu Sul OTH
- Dae Won Cho OTH (43)
- Ji Seong Park DRC (41)
- Man Sun Park DRC (40)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 18th, 1999
- Public Since
- January 26th, 2011
- No. of Shareholders
- 17,600
- No. of Employees
- 100
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 31,977,916
- Address
- 701-704, 5th JungAng Induspia, SEONGNAM, 13202
- Web
- https://www.intron.co.kr/
- Phone
- +82 317395678
- Auditors
- Shinhan Accounting Corporation
Upcoming Events for 048530
Q2 2025 iNtRON Biotechnology Inc Earnings Release
Similar to 048530
3Billion
Korea Exchange - KOSDAQ
ABion
Korea Exchange - KOSDAQ
ABL Bio
Korea Exchange - KOSDAQ
Amicogen
Korea Exchange - KOSDAQ
AprilBio Co
Korea Exchange - KOSDAQ
FAQ
What is the iNtRON Biotechnology share price?
As of Today at 21:21 UTC, shares in iNtRON Biotechnology are trading at KR₩4,165. This share price information is delayed by 15 minutes.
How has the iNtRON Biotechnology share price performed this year?
Shares in iNtRON Biotechnology last closed at KR₩4,165 and the price had moved by -39.64% over the past 365 days. In terms of relative price strength the iNtRON Biotechnology share price has underperformed the FTSE Developed Asia Pacific Index by -38.95% over the past year.
What are the analyst and broker recommendations for iNtRON Biotechnology?
The overall consensus recommendation for iNtRON Biotechnology is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the iNtRON Biotechnology dividend yield?
The iNtRON Biotechnology dividend yield is 2.4% based on the trailing twelve month period.
Does iNtRON Biotechnology pay a dividend?
Last year, iNtRON Biotechnology paid a total dividend of KR₩100, and it currently has a trailing dividend yield of 2.4%. We do not have any data on when iNtRON Biotechnology is to next pay dividends.
When does iNtRON Biotechnology next pay dividends?
We do not have data on when iNtRON Biotechnology is to next pay dividends. The historic dividend yield on iNtRON Biotechnology shares is currently 2.4%.
How do I buy iNtRON Biotechnology shares?
To buy shares in iNtRON Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of iNtRON Biotechnology?
As of the previous close price of KR₩4,165, shares in iNtRON Biotechnology had a market capitalisation of KR₩130bn.
Where are iNtRON Biotechnology shares listed?
Here are the trading details for iNtRON Biotechnology:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 048530
What kind of share is iNtRON Biotechnology?
Based on an overall assessment of its quality, value and momentum iNtRON Biotechnology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a iNtRON Biotechnology share price forecast for 2025?
The analyst consensus target price for shares in iNtRON Biotechnology is KR₩16,742. That is 301.96% above the last closing price of KR₩4,165.
Analysts covering iNtRON Biotechnology currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the iNtRON Biotechnology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like iNtRON Biotechnology. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -23.64%.
As of the last closing price of KR₩4,165, shares in iNtRON Biotechnology were trading -23.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the iNtRON Biotechnology PE Ratio?
The iNtRON Biotechnology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩4,165.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of iNtRON Biotechnology?
iNtRON Biotechnology's management team is headed by:
- Seong Jun Yoon - CEO
- Gyeong Won Yoon - MDR
- Sang Hyeon Kang - MDR
- Jae Gu Sul - OTH
- Dae Won Cho - OTH
- Ji Seong Park - DRC
- Man Sun Park - DRC